Exosomal lncRNA sequencing in Atorvastatin treated and non-treated MSC-derived exosomes

In order to investigate the molecular mechanisms underlying the further enhancement of Atorvastatin pretreated MSC-derived exosomes (MSCATV-Exo) in cardiac protection, we performed lncRNA sequencing on exosomes secreted from ATV pretreated MSCs and non treated MSCs to identify differentially expressed lncRNA. We found that 450 lncRNAs were identified to be upregulated and 1332 lncRNAs downregulated (over 1.5 fold change) in MSCATV-Exo compared to MSC-Exo. Overall design: Two samples were processed for each kind of exosomes that derived from normal MSCs and ATV pretreating MSCs (MSC-Exo and MSCATV-Exo). MSCATV-Exo was isolated from conditioned medium of MSCs pretreated by 1µmol/L of ATV for 24 hours. RNA isolated from exosomes were analyzed using Illumina HiSeq 2500.